Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 176 - 200 of 9482 in total
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … receptors (VEGF-R). ... Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. ... On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal …
Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride. Similar to other local anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential. The pharmacological profile of...
Approved
Investigational
Matched Description: … the nerve impulse and reducing the rate of rise of the action potential. ... anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of ... [L43402] The pharmacological profile of chloroprocaine is characterized by a short latency and duration …
Matched Categories: … Esters of Aminobenzoic Acid …
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Categories: … combinations of sulfonamides …
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … [A263071] Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of ... Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear ... factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of
Matched Categories: … Drugs for Treatment of Bone Diseases …
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Matched Categories: … combinations of sulfonamides …
A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.
Approved
Investigational
Vet approved
Matched Description: … It has a spectrum of antimicrobial action similar to other sulfonamides. …
Matched Categories: … combinations of sulfonamides …
Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Approved
Investigational
Matched Description: … It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic ... patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of
Matched Categories: … Diagnostic Uses of Chemicals …
Ioxaglic acid is marketed as Hexabrix. This drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opaque in its appearance on x-ray film, improving the visualization of important structures and organs during...
Approved
Investigational
Matched Description: … ioxaglic acid blocks x-rays and is opaque in its appearance on x-ray film, improving the visualization of
Matched Categories: … Diagnostic Uses of Chemicals …
Metrizoic acid is a molecule used as a contrast medium. It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA. One study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated. A total of...
Approved
Matched Description: … Seven cases of ventricular fibrillation, and 5 of significant bradycardia/asystole, were associated with ... It present a higher risk of allergic reactions due to its high osmolality. ... With two exceptions, all complications occurred during injection of the right coronary artery. …
Matched Categories: … Diagnostic Uses of Chemicals …
Quinupramine has been approved in France under the brand name Kinupril, as an antidepressant .
Approved
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Approved
Investigational
Matched Mixtures name: … FOLISTER COMPLEX HAIR LOTION (R) ... FOLISTER COMPLEX HAIR LOTION (R) …
Matched Products: … R-GER FORT 50 MG/ML SPREY, ÇÖZELTİ, 60 ML …
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Approved
Matched Description: … Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase ... Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (> …
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased...
Approved
Withdrawn
Matched Description: … It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic ... It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of ... Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. …
Matched Products: … เอสโมล็อค(R) …
Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from DB12604. The structure of plazomicin was established via appending hydroxylaminobutyric acid to DB12604 at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main...
Approved
Investigational
Matched Description: … However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ... The structure of plazomicin was established via appending hydroxylaminobutyric acid to [DB12604] at position ... 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of
A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.
Approved
Investigational
Matched Description: … was previously available internationally, however in most markets it has been phased out in favour of
Matched Categories: … Combined Inhibitors of Serotonin/Norepinephrine Reuptake ... Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Approved
Investigational
Matched Description: … It is marketed under the name Juxtapid (R). …
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer...
Approved
Investigational
Matched Description: … with severe cases of COVID-19. ... for the survival and proliferation of cancer cells. ... There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important …
Matched Products: … KRABEVA Bevacizumab (r-DNA Origin) Concentrate for Solution for Intravenous Infusion 25mg/mL …
Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects. Commonly marketed under the brand name Antivert in...
Approved
Matched Description: … It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular …
Matched Products: … VERTINON (R) 25 MG …
Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers....
Approved
Investigational
Matched Description: … its active (R;R)- and inactive (S;S)-enantiomers. ... of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of ... Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was …
Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved...
Approved
Investigational
Matched Description: … The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that …
Matched Categories: … Diagnostic Uses of Chemicals …
Technetium Tc 99m Mebrofenin is a diagnostic radiopharmaceutical composed of diisopropyl-iminodiacetic acid (DISIDA) attached to a technetium-99m ion. Following intravenous injection, single photon emission computer tomography (SPECT) imaging of the liver or gallbladder is performed using a gamma camera to detect the gamma rays emitted by the technetium-99m as it...
Approved
Matched Description: … Technetium Tc 99m Mebrofenin is a diagnostic radiopharmaceutical composed of diisopropyl-iminodiacetic ... Following intravenous injection, single photon emission computer tomography (SPECT) imaging of the liver ... More specifically, mebrofenin is taken up into hepatocytes through the action of OATP1B1 and OATP1B3 …
Matched Categories: … Diagnostic Uses of Chemicals …
Dibenzepin is approved for use in Europe.
Approved
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity....
Approved
Investigational
Matched Description: … gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of
Matched Categories: … Diagnostic Uses of Chemicals …
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in...
Approved
Matched Description: … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase ... developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of ... [L45889] It is currently approved for the treatment of various conditions, such as chronic lymphocytic …
Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis.
Approved
Matched Description: … It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. …
Matched Categories: … combinations of xanthines …
Displaying drugs 176 - 200 of 9482 in total